AIDS Vaccine Week articles from April 2009

AIDS Vaccine Week archives from April 2009

Confirmation of Bogoch Replikins Influenza Patents by Harvard-CDC and Scripps-Crucell Data.
April 6, 2009... Replikins, Ltd. announced that data recently published from Harvard-CDC and Scripps-Crucell in Nature(1) and Science(2) confirms the 2001 discoveries by Dr. Samuel and Elenore Bogoch of peptides in the hemagglutinin unit of influenza, which...

Data from A. Fernandezgarcia et al provide new insights into HIV/AIDS.(Report)
April 6, 2009... "The aim of this study was the development of a panel constituted by well-defined HIV-1 strains of different genetic forms, with a particular focus on isolates from acute and recent infections. Fourteen HIV-1 isolates, including four from acute...

Reports from University of Cape Town describe recent advances in HIV/AIDS.(Report)
April 6, 2009... According to recent research from South Africa, "Candidate human immunodeficiency virus (HIV) vaccine regimens based on DNA boosted with recombinant modified vaccinia Ankara (MVA) have been in development for some time, and there is evidence...

Research from Centers for Disease Control and Prevention yields new findings on HIV/AIDS.(Report)
April 6, 2009... "We previously observed limited cross-reactive T cell responses in two HIV-1-superinfected injection drug users (IDUs) before superinfection [Ramos A, et al.: J Virol 2002; 76(15): 7444-7452]. To elucidate the role of such responses in...

Research on HIV/AIDS described by scientists at Johns Hopkins University.
April 6, 2009... According to recent research published in the journal AIDS Research and Human Retroviruses, "Vaccines inducing pathogen-specific cell-mediated immunity are being developed using attenuated adenoviral (Ad) vectors. We report the results of two...

Scientists at Baylor College of Medicine, College of Medicine report research in HIV/AIDS.
April 6, 2009... "We reviewed selected reports in the field of basic and clinical immunology published in 2008. Research progress in the immunologic mechanisms of allergic disease included the modulation of T(H)2 responses by specific transcription factors and...

Aphios Corporation Executes Collaborative R&D Agreement with VivaCell Biotechnology Espana to Develop Combination Therapy for HIV Latency.
April 6, 2009... Aphios Corporation announced entering into a Collaborative Research and Development Agreement with VivaCell Biotechnology Espana S.L., Cordoba, Spain to develop a combination therapy for the treatment of HIV latency (see also Aphios...

ImQuest Presentations at Keystone Symposium Focus on Advancements in Their Therapeutic and Microbicide Development Programs.
April 6, 2009... ImQuest Life Sciences presented their latest biological results supporting the continued development of their small molecule pyrimidinedione inhibitors of HIV-1 at the Prevention of meeting being held in Keystone, Colorado. The presentations...

New cancer vaccines study results from Uppsala University described.
April 13, 2009... According to recent research published in the International Journal of STD & AIDS, "The aim of the study was to investigate knowledge of and attitudes to sexually transmitted infection (STI) and STI prevention with special focus on human...

New findings from University of Mannheim in the area of HIV/AIDS described.(Report)
April 13, 2009... According to recent research from Mannheim, Germany, "AIDS continues to have a devastating effect on developing countries, particularly in sub-Saharan Africa. The lack of a proven effective vaccine to stop HIV transmission has led to much of...

Reports outline HIV/AIDS study results from Indiana University.
April 13, 2009... According to a study from the United States, "The acquired-immunodeficiency syndrome has evolved into a major worldwide epidemic. Significant effort has been made in the development of antiviral therapies." "A new strategy for vaccine and...

Scientists at National Institutes of Health report research in HIV/AIDS.
April 13, 2009... "An effective AIDS vaccine must control highly diverse circulating strains of human immunodeficiency virus type 1 (HIV-1). Among HIV-1 gene products, the envelope (Env) protein contains variable as well as conserved regions," scientists writing...

Studies from Yale University, Medical Department in the area of HIV/AIDS described.
April 13, 2009... According to recent research from the United States, "We assessed risk behaviour in a heterosexual cohort undergoing prescreening for the first Phase I/II HIV vaccine trials in Soweto. We developed a survey and collected self-reported data from...

Education Slowing AIDS in Sub-Saharan Africa.
April 13, 2009... Increased schooling across sub-Saharan Africa may be lowering new HIV infections among younger adults, according to sociologists, suggesting a shift in a decades-long trend where formal education is considered an AIDS risk factor (see also...

Immunotech Completes Merger Acquisition.
April 13, 2009... Immunotech Laboratories, Inc.(Pink Sheets: IMMB) has completed a reverse merger with a public shell company and has restructured its position through a 100 to 1 reverse split of stock. The company has issued 60 million authorized shares...

Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal Spray.
April 13, 2009... Viroblock SA has announced that the first generation of VCCD Tech antiviral nasal spray formulation is active against human influenza. Viroblock's patented Cholesterol Catalytic Depletion Technology (VCCD Tech) inactivates enveloped viruses...

Spaltudaq Corp. Announces Identification of Broadly and Potently Neutralizing Human HIV Antibodies and Change of Company Name to Theraclone Sciences, Inc.
April 13, 2009... Theraclone Sciences, a biopharmaceutical company formerly known as Spaltudaq, focused on the discovery and development of human antibodies, announced results from its HIV antibody discovery program at the HIV Immunobiology Meeting of the...

Research from Yale University broadens understanding of HIV/AIDS.
April 20, 2009... "The combination of tenofovir and emtricitabine shows promise as HIV preexposure prophylaxis (PrEP). We sought to forecast clinical, epidemiologic, and economic outcomes of PrEP, taking into account uncertainties regarding efficacy, the risks...

Researchers at Emory University, Emory Vaccine Center release new data on HIV/AIDS.(Clinical report)
April 20, 2009... According to recent research published in the Jaids - Journal of Acquired Immune Deficiency Syndromes, "The Step Study, a Phase IIb HIV vaccine proof of concept study, enrolled approximately 3000 persons in clade B regions. The Atlanta site...

Data on HIV/AIDS co-infection detailed by researchers at Oregon Health & Science University.
April 20, 2009... According to recent research from the United States, "The rapid onset of massive, systemic viral replication during primary HIV or simian immunodeficiency virus (SIV) infection and the immune evasion capabilities of these viruses pose...

HIV pays a price for invisibility.
April 27, 2009... Mutations that help HIV hide from the immune system undermine the virus's ability to replicate, show an international team of researchers in the April 13 issue of the Journal of Experimental Medicine. The study was published online on March 23...

Tijuana injection drug users on collision course for HIV and TB.
April 27, 2009... A study by researchers from the University of California, San Diego School of Medicine, in collaboration with Mexican researchers and health officials, shows that as many as 67 percent of injection drug users in Tijuana test positive for...

New HIV/AIDS research reported from M. Suhadev and co-authors.
April 27, 2009... "Successful conduct of any HIV vaccine trial (HIVVT) requires a high level of preparedness in the community. A cross-sectional study was conducted in Tamilnadu, India among 501 participants from six different risk groups to investigate their...

New HIV/AIDS study findings have been reported by scientists at National Institutes of Health.
April 27, 2009... According to a study from the United States, "Studies on human immunodeficiency virus type 1 (HIV-1) diversity are critical for understanding viral pathogenesis and the emergence of immune escape variants and for design of vaccine strategies....

Research from World Health Organization broadens understanding of HIV/AIDS.
April 27, 2009... "HIV vaccines of the first generation are, in contrast to most currently licensed vaccines, unlikely to provide sterilizing immunity against infection with HIV. However, they are expected to exert a beneficial effect on the maintenance of CD4...

Research from University of Minnesota, Medical Department has provided new data on life sciences.
April 27, 2009... According to a study from the United States, "In the early stages of viral infection, outcomes depend on a race between expansion of infection and the immune response generated to contain it." "We combined in situ tetramer staining with in...

Childrens Healthcare of Atlanta Names Paul W. Spearman, M.D. as Chief Research Officer.
April 27, 2009... Children's Healthcare of Atlanta and Emory University's Woodruff Health Sciences Center have appointed Paul W. Spearman, MD, as Chief Research Officer for Children's Healthcare of Atlanta and as Vice Chair of Research in the Department of...

HIV handicaps itself to escape immune system pressure.
April 27, 2009... People with the ability to stave off AIDS for years after initial infection by HIV have been called "long-term non-progressors" or "elite controllers." One component of this remarkable resistance comes from an individual's HLA genes....